Catalyst Pharmaceuticals Community
Our community narratives are driven by numbers and valuation.
Value any stock for free in seconds
Get alerts and valuation updates
Participate in discussions
WA
Based on Analyst Price Targets
FIRDAPSE And AGAMREE Lead Global Biotech Expansion With Promising Revenue Surge
Key Takeaways Strong performance and international expansion of FIRDAPSE, especially into Japan, are positioned to increase global revenue streams for Catalyst. Strategic partnerships and global market expansion, including new product launches, promise to enhance revenue and broaden Catalyst's portfolio.
View narrativeUS$31.86
FV
32.9% undervalued intrinsic discount13.81%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
7 days ago author updated this narrative